Q2/2024 6/30/2024 EPS -1.090 ZacksConsensus -1.020 ActVsEst (0.070) - Miss
Neurogene Inc. (NGNE)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $65.00 to $60.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Leerink Partners from $45.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at HC Wainwright from $49.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Robert W. Baird from $54.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
NGNE
Earnings
- 5/10/24 - Beat
NGNE
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- 11/8/24 - Form SC
- NGNE's page on the SEC website